Caris Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	649.06	412.26	306.13	258.49
Revenue Growth (YoY)	112.02%	34.67%	18.43%	-
Cost of Revenue	258.46	231.83	214.87	178.46
Gross Profit	390.6	180.43	91.26	80.02
Selling, General & Admin	376.51	326.05	296.04	294.51
Research & Development	94.43	111.5	114.77	101.27
Operating Expenses	470.95	437.55	410.81	395.78
Operating Income	-80.34	-257.12	-319.55	-315.76
Interest Expense	-58.76	-50.03	-31.61	-26.68
Interest & Investment Income	10.45	7.12	11.26	0.95
Other Non Operating Income (Expenses)	-40.41	18.14	9.4	20.66
EBT Excluding Unusual Items	-169.06	-281.89	-330.5	-320.83
Other Unusual Items	-17.93	-	-10.92	-
Pretax Income	-186.99	-281.89	-341.42	-320.83
Net Income	-186.99	-281.89	-341.42	-320.83
Preferred Dividends & Other Adjustments	494.87	96.37	121.11	79
Net Income to Common	-681.86	-378.26	-462.53	-399.83
Shares Outstanding (Basic)	105	35	35	33
Shares Outstanding (Diluted)	105	35	35	33
Shares Change (YoY)	201.21%	1.59%	4.73%	-
EPS (Basic)	-6.48	-10.66	-13.24	-11.98
EPS (Diluted)	-6.48	-10.66	-13.24	-11.98
Free Cash Flow	-14.01	-253.64	-298.42	-327.96
Free Cash Flow Per Share	-0.13	-7.15	-8.54	-9.83
Gross Margin	60.18%	43.77%	29.81%	30.96%
Operating Margin	-12.38%	-62.37%	-104.38%	-122.16%
Profit Margin	-105.05%	-91.75%	-151.09%	-154.68%
Free Cash Flow Margin	-2.16%	-61.52%	-97.48%	-126.88%
EBITDA	-52.95	-208.21	-270.55	-267.5
EBITDA Margin	-8.16%	-50.50%	-88.38%	-103.49%
D&A For EBITDA	27.39	48.91	49	48.25
EBIT	-80.34	-257.12	-319.55	-315.76
EBIT Margin	-12.38%	-62.37%	-104.38%	-122.16%
Revenue as Reported	649.06	412.26	306.13	258.49
Advertising Expenses	-	1.2	0.6	1

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q